Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment

Abstract Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing finding effective drugs with reduced side effects and lower costs. Colorectal cancer (CRC) is often diagnosed at adv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L. E. Anselmino, M. V. Baglioni, F. Malizia, N. Cesatti Laluce, C. Borini Etichetti, V. L. Martínez Marignac, V. Rozados, O. G. Scharovsky, J. Girardini, M. J. Rico, M. Menacho Márquez
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/93cfc863cbba48eda474cd3a9008e6b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:93cfc863cbba48eda474cd3a9008e6b4
record_format	dspace
spelling	oai:doaj.org-article:93cfc863cbba48eda474cd3a9008e6b42021-12-02T18:02:57ZRepositioning metformin and propranolol for colorectal and triple negative breast cancers treatment10.1038/s41598-021-87525-z2045-2322https://doaj.org/article/93cfc863cbba48eda474cd3a9008e6b42021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87525-zhttps://doaj.org/toc/2045-2322Abstract Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing finding effective drugs with reduced side effects and lower costs. Colorectal cancer (CRC) is often diagnosed at advanced stages, when the probability of chemotherapy resistance is higher. Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, highly metastatic and difficult to treat. For both tumor types, available treatments are generally associated to severe side effects. In our work, we explored the effect of combining metformin and propranolol, two repositioned drugs, in both tumor types. We demonstrate that treatment affects viability, epithelial-mesenchymal transition and migratory potential of CRC cells as we described before for TNBC. We show that combined treatment affects different steps leading to metastasis in TNBC. Moreover, combined treatment is also effective preventing the development of 5-FU resistant CRC. Our data suggest that combination of metformin and propranolol could be useful as a putative adjuvant treatment for both TNBC and CRC and an alternative for chemo-resistant CRC, providing a low-cost alternative therapy without associated toxicity.L. E. AnselminoM. V. BaglioniF. MaliziaN. Cesatti LaluceC. Borini EtichettiV. L. Martínez MarignacV. RozadosO. G. ScharovskyJ. GirardiniM. J. RicoM. Menacho MárquezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q L. E. Anselmino M. V. Baglioni F. Malizia N. Cesatti Laluce C. Borini Etichetti V. L. Martínez Marignac V. Rozados O. G. Scharovsky J. Girardini M. J. Rico M. Menacho Márquez Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
description	Abstract Drug repositioning refers to new uses for existing drugs outside the scope of the original medical indications. This approach fastens the process of drug development allowing finding effective drugs with reduced side effects and lower costs. Colorectal cancer (CRC) is often diagnosed at advanced stages, when the probability of chemotherapy resistance is higher. Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, highly metastatic and difficult to treat. For both tumor types, available treatments are generally associated to severe side effects. In our work, we explored the effect of combining metformin and propranolol, two repositioned drugs, in both tumor types. We demonstrate that treatment affects viability, epithelial-mesenchymal transition and migratory potential of CRC cells as we described before for TNBC. We show that combined treatment affects different steps leading to metastasis in TNBC. Moreover, combined treatment is also effective preventing the development of 5-FU resistant CRC. Our data suggest that combination of metformin and propranolol could be useful as a putative adjuvant treatment for both TNBC and CRC and an alternative for chemo-resistant CRC, providing a low-cost alternative therapy without associated toxicity.
format	article
author	L. E. Anselmino M. V. Baglioni F. Malizia N. Cesatti Laluce C. Borini Etichetti V. L. Martínez Marignac V. Rozados O. G. Scharovsky J. Girardini M. J. Rico M. Menacho Márquez
author_facet	L. E. Anselmino M. V. Baglioni F. Malizia N. Cesatti Laluce C. Borini Etichetti V. L. Martínez Marignac V. Rozados O. G. Scharovsky J. Girardini M. J. Rico M. Menacho Márquez
author_sort	L. E. Anselmino
title	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_short	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_full	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_fullStr	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_full_unstemmed	Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
title_sort	repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/93cfc863cbba48eda474cd3a9008e6b4
work_keys_str_mv	AT leanselmino repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT mvbaglioni repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT fmalizia repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT ncesattilaluce repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT cborinietichetti repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT vlmartinezmarignac repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT vrozados repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT ogscharovsky repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT jgirardini repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT mjrico repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment AT mmenachomarquez repositioningmetforminandpropranololforcolorectalandtriplenegativebreastcancerstreatment
_version_	1718378822631424000

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment

Ejemplares similares